Multidrug-Resistant and Extended Spectrum β-Lactamase Producing Escherichia coli and Klebsiella pneumoniae Isolates from Urine Samples of Hospital Patients
Keywords:
Escherichia coli, Extended Spectrum β-lactamase (ESBL), Klebsiella pneumoniae, Multidrug resistance (MDR), Urinary Tract Infection (UTI)Abstract
Multi drug resistant Escherichia coli and Klebsiella pneumoniae expressing extended spectrum β- lactamase enzymes (ESBLs) has become a serious challenge to clinicians for the therapeutic management of clinical cases in urinary tract infection.
The main objective of the study was focused to determine the dominance of MDR E. coli and Klebsiella pneumoniae and the evaluation of status of β-lactamase enzyme produced by them.
The study was carried out in Holy family hospital and Khalifa gul Nawaz hospital, Pakistan, between June and November 2023. A total of 350 midstream urine samples were processed among suspected cases of urinary tract infection. The bacteria were isolated by semi quantitively culture technique and identified by conventional biochemical tests. The antimicrobial susceptibility testing was performed by modified Kirby Bauer disc diffusion method following Clinical and Laboratory Standards Institute guidelines and were tested for ESBL by combination disc method. The pvalue <0.05 was considered as statistically significant.
A total of 85 samples showed significant bacteriuria with 62 E. coli and 23 Klebsiella pneumoniae. Among the isolates, 62.35% were found MDR strains. By combined disk test, 86.67% E. coli and 13.33% Klebsiella spp. were found ESBL producers. There is significant association between MDR and ESBL production as well as between age group of patients and ESBL producing organisms (P=0.01). Higher prevalence of ESBL producing E. coli and Klebsiella spp. Was observed warranting prompt need of surveillance for effective management of such MDR strains. Imipenem, Meropenem and Nitrofurantoin seemed to be drug of choice for UTI. Amoxycillin should no longer considered as drugs for empirical treatment of clinically evident UTI, because of high resistance rates.
There is an increasing need for periodic monitoring of drug susceptibility patterns to prevent the spread and development of antimicrobial resistant strains and ESBL producers.
Downloads
References
Ademola, B. L., Atanda, A. T., Aji, S. A., & Abdu, A. (2020). Clinical, morphologic and histological features
of chronic pyelonephritis: An 8-year review. Nigerian Postgraduate Medical Journal, 27(1), 37-
Aminzadeh, Z., Kashi, M. S., & SHAABANI, M. (2008). Bacteriuria by extended-spectrum beta-lactamaseproducing Escherichia coli and Klebsiella pneumoniae isolates in a governmental hospital in
south of Tehran, Iran.
Awasthi, T. R., Pant, N. D., & Dahal, P. R. (2015). Prevalence of multidrug resistant bacteria in causing
community acquired urinary tract infection among the patients attending outpatient
Department of Seti Zonal Hospital, Dhangadi, Nepal. Nepal journal of biotechnology, 3(1), 55-59.
Baral, P., Neupane, S., Marasini, B. P., Ghimire, K. R., Lekhak, B., & Shrestha, B. (2012). High prevalence
of multidrug resistance in bacterial uropathogens from Kathmandu, Nepal. BMC Research notes,
, 1-9.
Bawankar, S., Enam, S. K., Panda, A., & Chandi, D. H. (2016). Bacteriological study of uropathogens with
correlation of various screening test with culture and their antimicrobial susceptibility. Asian
Journal of Medical Sciences, 7(3), 108-114.
Bell, J. M., Chitsaz, M., Turnidge, J. D., Barton, M., Walters, L. J., & Jones, R. N. (2007). Prevalence and
significance of a negative extended-spectrum β-lactamase (ESBL) confirmation test result after a
positive ESBL screening test result for isolates of Escherichia coli and Klebsiella pneumoniae:
results from the SENTRY Asia-Pacific surveillance program. Journal of clinical microbiology, 45(5),
-1482.
Bhardwaj, S., Mehra, P., Dhanjal, D. S., Sharma, P., Sharma, V., Singh, R., . . . Kua, K. (2022). Antibiotics
and antibiotic resistance-flipsides of the same coin. Current Pharmaceutical Design, 28(28),
-2329.
Braunwald, E., Fauci, A., Kasper, D., Hauser, S., Longo, D., & Jameson, L. (2001). Harrison's principles of internal medicine 15th. NY: McGraw-Hill Book Company.
Chander, A., & Shrestha, C. D. (2013). Prevalence of extended spectrum beta lactamase producing
Escherichia coli and Klebsiella pneumoniae urinary isolates in a tertiary care hospital in
Kathmandu, Nepal. BMC Research notes, 6, 1-6.
Chhetri, P., Rai, S., Pathak, U., Thapa, J., Devkota, K., Shrestha, B., & Shrestha, R. (2001). Retrospective
study on urinary tract infection at Nepal Medical College Teaching Hospital, Kathmandu. Nepal
Med Coll J, 3(83), 5.
Dalela, G. (2012). Prevalence of extended spectrum beta-lactamase (ESBL) producers among gramnegative bacilli from various clinical isolates in a tertiary care hospital at Jhalawar, Rajasthan,
India. J Clin Diagn Res, 6(2), 182-187.
Forbes, B. A., Sahm, D. F., & Weissfeld, A. S. (2007). Diagnostic microbiology: Mosby St Louis.
Habte, T., Dube, S., Ismail, N., & Hoosen, A. A. (2009). Hospital and community isolates of uropathogens
at a tertiary hospital in South Africa. South African Medical Journal, 99(8).
Hudson, C., & Mortimore, G. (2020). The diagnosis and management of a patient with acute
pyelonephritis. British Journal of Nursing, 29(3), 144-150.
Kader, A. A., & Angamuthu, K. (2005). Extended-spectrum beta-lactamases in urinary isolates of
Escherichia coli, Klebsiella pneumoniae and other gram-negative bacteria in a hospital in Eastern
Province, Saudi Arabia. Saudi medical journal, 26(6), 956-959.
Karki, R. (2023). MULTIDRUG RESISTANCE AND EXTENDED SPECTRUM β-LACTAMASE PRODUCING
ESCHERICHIA COLI AND KLEBSIELLA PNEUMONIAE ISOLATES FROM URINE SAMPLES OF
PATIENTS ATTENDING A HOSPITAL OF SUNSARI, NEPAL. Department of Microbiology Central
Campus of Technology, Dharan, Nepal TU …,
Kayastha, K., Dhungel, B., Karki, S., Adhikari, B., Banjara, M. R., Rijal, K. R., & Ghimire, P. (2020).
Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species in pediatric
patients visiting International Friendship Children’s Hospital, Kathmandu, Nepal. Infectious
Diseases: Research and Treatment, 13, 1178633720909798.
Klein, R. D., & Hultgren, S. J. (2020). Urinary tract infections: microbial pathogenesis, host–pathogen
interactions and new treatment strategies. Nature Reviews Microbiology, 18(4), 211-226.
Martins, C. G. d. R. S. (2021). Nosocomial and community-acquired urinary tract infections.
Mukherjee, M., BaSu, S., MuKherjee, S. K., & MajuMder, M. (2013). Multidrug-resistance and extended
spectrum beta-lactamase production in uropathogenic E. coli which were isolated from
hospitalized patients in Kolkata, India. Journal of clinical and diagnostic research: JCDR, 7(3),
Niranjan, V., & Malini, A. (2014). Antimicrobial resistance pattern in Escherichia coli causing urinary tract
infection among inpatients. Indian Journal of Medical Research, 139(6), 945-948.
Öztürk, R., & Murt, A. (2020). Epidemiology of urological infections: a global burden. World journal of
urology, 38, 2669-2679.
Parajuli, N. P., Maharjan, P., Parajuli, H., Joshi, G., Paudel, D., Sayami, S., & Khanal, P. R. (2017). High
rates of multidrug resistance among uropathogenic Escherichia coli in children and analyses of
ESBL producers from Nepal. Antimicrobial Resistance & Infection Control, 6, 1-7.
Paudel, S. (2013). Status of extended spectrum beta latamase producing Enterobacteraceae among
bacterial Uropathogens. Central Department of Microbiology, TU, Kirtipur, Nepal, 23-55.
Rawat, D., Hasan, A. S., Capoor, M. R., Sarma, S., Nair, D., Deb, M., . . . Aggarwal, P. (2009). In vitro
evaluation of a new cefixime-clavulanic acid combination for gram-negative bacteria. Southeast
Asian journal of tropical medicine and public health, 40(1), 131.
Shakya, P., Shrestha, D., Maharjan, E., Sharma, V. K., & Paudyal, R. (2017). ESBL production among E. coli
and Klebsiella spp. causing urinary tract infection: a hospital based study. The open microbiology
journal, 11, 23.
Shankar, P., Partha, P., & Shenoy, N. (2002). Self-medication and non-doctor prescription practices in
Pokhara valley, Western Nepal: a questionnaire-based study. BMC family practice, 3, 1-7.
Sharma, A. R., Bhatta, D. R., Shrestha, J., & Banjara, M. R. (2013). Antimicrobial susceptibility pattern of
Escherichia coli isolated from urinary tract infected patients attending Bir Hospital. Nepal J Sci
Technol, 14(1), 177-184.
Singh, P., & Holmen, J. (2022). Multidrug-resistant infections in the developing world. Pediatric Clinics,
(1), 141-152.
Singh, V., Tuladhar, R., & Chaudhary, M. (2015). Beta lactamase producing Escherichia coli, Klebsiella
pneumoniae and methicillin resistant Staphylococcus aureus among uropathogens. Nepal
Journal of Science and Technology, 16(1), 105-112.
Ullah, F., Malik, S., & Ahmed, J. (2009). Antibiotic susceptibility pattern and ESBL prevalence in
nosocomial Escherichia coli from urinary tract infections in Pakistan. African Journal of
Biotechnology, 8(16).
Von Baum, H., & Marre, R. (2005). Antimicrobial resistance of Escherichia coli and therapeutic
implications. International Journal of Medical Microbiology, 295(6-7), 503-511.
Yadav, K. K., Adhikari, N., Khadka, R., Pant, A. D., & Shah, B. (2015). Multidrug resistant
Enterobacteriaceae and extended spectrum β-lactamase producing Escherichia coli: a crosssectional study in National Kidney Center, Nepal. Antimicrobial resistance and infection control,
, 1-7.
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
